TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35468690

Group type: EXPERIMENTAL
Intervention: Enriched BMA-matrix (CE group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultured autologous bone marrow MSCs matrix (CC group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discectomy only (DO group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-injured control (NC group)
Number of subjects: 0
Study: 35468801

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 0
Study: 35468860

Group type: EXPERIMENTAL
Intervention: COVID-19 disruptions at the structural and community level
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Qualitative themes from interviews
Number of subjects: 50
Study: 35469060

Group type: EXPERIMENTAL
Intervention: Lecanemab + Standard of Care (SoC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 35469288

Group type: COMPARATOR
Intervention: Intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab and suprachoroidal injection of triamcinolone acetonide (4mg/0.1mL)
Number of subjects: 60
Study: 35469391

Group type: EXPERIMENTAL
Intervention: Visual EEG assessment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual grading of MRI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ADC analysis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EEG and MRI combined
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ischemic damage in cortical gray matter
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ischemic damage in deep gray nuclei
Number of subjects: 50
Study: 35469443

Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin plus oral tapering of phenytoin
Number of subjects: 15
Study: 35469846

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: VAS2870 (NADPH oxidase inhibitor)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no antioxidant treatment)
Number of subjects: 2
Study: 35470214

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 12206

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 12206
Study: 35470225

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate 30 mg plus meloxicam 30 mg
Number of subjects: 9
Study: 35470301

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk-stratification system
Number of subjects: 0
Study: 35470686

Group type: EXPERIMENTAL
Intervention: Post-PCI hemodynamic assessment
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Thermodilution time at 30 minutes post-PCI
Number of subjects: 57
Study: 35470715

Group type: EXPERIMENTAL
Intervention: Heart Failure (HF)
Number of subjects: 3959
Study: 35470855

Group type: EXPERIMENTAL
Intervention: High consumption of ultra-processed foods (721 ± 341 g/d, 28% of total food intake)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Desserts
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Processed meats
Number of subjects: 632
Study: 35470975

Group type: EXPERIMENTAL
Intervention: Unilateral cycling at 70% maximal oxygen uptake for 30 minutes
Number of subjects: 8
Study: 35471132

Group type: EXPERIMENTAL
Intervention: Germline testing for cancer predisposition
Number of subjects: 0
Study: 35471240

Group type: EXPERIMENTAL
Intervention: Active Video Game (AVG) intervention combined with multicomponent exercise for 5 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (daily activities without modification)
Number of subjects: 28
Study: 35471625

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg, 100 mg, 200 mg
Number of subjects: 5704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5704
Study: 35472208

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 152
Study: 35472215

Group type: EXPERIMENTAL
Intervention: modified WHO (mWHO) risk score
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CARPREG II risk score
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HARRIS risk score
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ZAHARA risk score
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CARPREG risk score
Number of subjects: 65
Study: 35472243

Group type: EXPERIMENTAL
Intervention: PolyPEPI1018 and Montanide ISA51VG adjuvant subcutaneously, combined with fluoropyrimidine/biologic
Number of subjects: 11
Study: 35472295

Group type: COMPARATOR
Intervention: New Covid-19 vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active controls (existing vaccines)
Number of subjects: 0
Study: 35473396

Group type: EXPERIMENTAL
Intervention: Thyroid-Stimulating Hormone and Thyroid Hormones
Number of subjects: 0
Study: 35473676

Group type: EXPERIMENTAL
Intervention: Beta-blockers (prescribed)
Number of subjects: 2519

Group type: COMPARATOR
Intervention: Beta-blockers (unprescribed)
Number of subjects: 2519
Study: 35473709

Group type: EXPERIMENTAL
Intervention: Corticosteroids (modified to use non-fluorinated glucocorticoids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Il-6 inhibitors and monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific antiviral therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis against venous thromboembolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respiratory support (oxygen, non-invasive ventilation, prone position ventilation, intubation, ECMO)
Number of subjects: 0
Study: 35473726

Group type: EXPERIMENTAL
Intervention: CL2020 cells (1.5 million cells for low-dose cohort, 15 million cells for high-dose cohort)
Number of subjects: 12
Study: 35473725

Group type: EXPERIMENTAL
Intervention: National Early Warning Score (NEWS)
Number of subjects: 18889

Group type: EXPERIMENTAL
Intervention: NEWS's respiratory rate component
Number of subjects: 18889

Group type: EXPERIMENTAL
Intervention: NEWS's individual score components
Number of subjects: 18889
Study: 35474180

Group type: EXPERIMENTAL
Intervention: mRS >1 at 30 days and mRS 0-1 at 90 days OR mRS >2 at 30 days and mRS 0-2 at 90 days
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: mRS 1 at 30 days to 2 at 90 days
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Overall agreement in mRS between 30 and 90 days
Number of subjects: 1339
Study: 35474746

Group type: EXPERIMENTAL
Intervention: Anecdotal evidence and social media guidelines (Era 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preprints and accelerated interventions (Era 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Living, online clinical guidelines (Current Era)
Number of subjects: 0
Study: 35475155

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy
Number of subjects: 492
Study: 35475157

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/day) + ADT
Number of subjects: 206

Group type: COMPARATOR
Intervention: Flutamide (375 mg/day) + ADT
Number of subjects: 206
Study: 35475300

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB with ropivacaine + plain lubricant)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Combination group (DPNB with ropivacaine + tetracaine gel)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Tetracaine gel group (DPNB with saline)
Number of subjects: 258
Study: 35475358

Group type: EXPERIMENTAL
Intervention: Coronary Microvascular Dysfunction (CMD)
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: INOCA (Ischemia with Nonobstructive Coronary Arteries)
Number of subjects: 2322

Group type: EXPERIMENTAL
Intervention: Major adverse cardiovascular events (MACE)
Number of subjects: 2322
Study: 35475570

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 35475789

Group type: EXPERIMENTAL
Intervention: Active transcranial alternating current stimulation with cognitive treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham transcranial alternating current stimulation
Number of subjects: 75
Study: 35475885

Group type: EXPERIMENTAL
Intervention: Treg DLI plus low-dose interleukin-2 (LD IL-2)
Number of subjects: 25
Study: 35475910

Group type: EXPERIMENTAL
Intervention: IL-15 (0.5, 1, and 2 μg/kg subcutaneously 5 days per week for 2 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: IL-15
Number of subjects: 11
Study: 35475982

Group type: EXPERIMENTAL
Intervention: Simulation-based training (40-minute immersive individual simulation training focusing on high-risk medications in older adults)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (online educational training)
Number of subjects: 36
Study: 35476034

Group type: EXPERIMENTAL
Intervention: Adequate sleep (7-9 hours/night) and activity (>5000 steps/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adequate sleep (7-9 hours/night) but less activity (<5000 steps/day)
Number of subjects: 120
Study: 35476127

Group type: EXPERIMENTAL
Intervention: WT1 recombinant protein vaccination (WT1-A10) with vaccine adjuvant AS01
Number of subjects: 0
Study: 35476252

Group type: EXPERIMENTAL
Intervention: Antiestrogen hormonal therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (non-cancer group)
Number of subjects: 29
Study: 35476455

Group type: EXPERIMENTAL
Intervention: Infusion needle ablation (INA)
Number of subjects: 35
Study: 35476550

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for ER+/Basal tumors (15% of ER+, HER2- tumors reclassified by 80-GS)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Neoadjuvant therapy for ER+/Luminal subtype
Number of subjects: 1069
Study: 35476823

Group type: EXPERIMENTAL
Intervention: ECHO
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: ECHO Plus
Number of subjects: 136
Study: 35476981

Group type: EXPERIMENTAL
Intervention: Germ-free mice introduced with a consortium of 26 human gut bacterial strains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute malnutrition
Number of subjects: 0
Study: 35476994

Group type: EXPERIMENTAL
Intervention: HIV-infected cell clones
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Different assays for clonal expansion
Number of subjects: 4
Study: 35477163

Group type: EXPERIMENTAL
Intervention: Quick Dementia Rating System (QDRS)
Number of subjects: 121
Study: 35477175

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) alone for 6 months
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination therapy of Hydroxyurea (HU) and thalidomide for 6 months
Number of subjects: 135
Study: 35477368

Group type: EXPERIMENTAL
Intervention: Preoperative binocular vision measures including stereopsis, ocular alignment, fusional vergence, vergence facility, convergence amplitude, and symptom survey.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Decreased vergence facility and convergence amplitude compared to pre-presbyopes.
Number of subjects: 73
Study: 35477380

Group type: EXPERIMENTAL
Intervention: HIP-REP intervention based on Activity of Daily Living
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 35477432

Group type: EXPERIMENTAL
Intervention: Long course neoadjuvant chemoradiotherapy (NCRT) plus tislelizumab followed by total mesorectal excision (TME)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Long course neoadjuvant chemoradiotherapy (NCRT)
Number of subjects: 50
Study: 35477725

Group type: EXPERIMENTAL
Intervention: MAD0004J08 (single dose via intramuscular injection)
Number of subjects: 0
Study: 35478081

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (BGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite comparator (LAMA/LABA therapies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BGF
Number of subjects: 0
Study: 35478493

Group type: COMPARATOR
Intervention: Maternal obesity (OW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher α-diversity and specific microbial taxa at 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal HMO concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elevated maternal BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall microbial richness
Number of subjects: 0
Study: 35478711

Group type: EXPERIMENTAL
Intervention: CCCG-LBL-2016 regimen combined with dasatinib and prophylactic intrathecal infusion
Number of subjects: 1

Group type: COMPARATOR
Intervention: CCCG-LBL-2016 regimen
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: BCR-ABL tyrosine kinase inhibitor (TKI) dasatinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: TBI-based haploidentical allogeneic hematopoietic stem cell transplantation (haplo-allo-HSCT)
Number of subjects: 1
Study: 35479184

Group type: EXPERIMENTAL
Intervention: rTMS/Sham SS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sham rTMS/SS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rTMS/SS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS/Sham SS
Number of subjects: 40
Study: 35479300

Group type: EXPERIMENTAL
Intervention: PTSD+ participants looking at sad eyes
Number of subjects: 159

Group type: COMPARATOR
Intervention: PTSD- participants looking at sad eyes
Number of subjects: 159

Group type: COMPARATOR
Intervention: Non-exposed participants looking at sad eyes
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Correlation of avoidance symptoms with attention to sad eyes
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Attention to neutral and happy faces
Number of subjects: 159
Study: 35480072

Group type: COMPARATOR
Intervention: 3DCRT (three-dimensional conformal radiotherapy)
Number of subjects: 300

Group type: COMPARATOR
Intervention: IMRT (intensity modulated radiotherapy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MOSES > 0.20
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: C-MOSES > 0.70
Number of subjects: 300
Study: 35480074

Group type: EXPERIMENTAL
Intervention: Higher intraoperative mechanical power
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Time-weighted average driving pressure
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Composite of postoperative pulmonary complications
Number of subjects: 1191
Study: 35480078

Group type: EXPERIMENTAL
Intervention: Updated risk prediction model for malignant esophageal lesions
Number of subjects: 20000
Study: 35481400

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 43
Study: 35481559

Group type: EXPERIMENTAL
Intervention: Algorithm for automatic detection of atrial fibrillation using a single-lead electrocardiogram from a smartwatch
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Single-lead electrocardiogram
Number of subjects: 262
Study: 35481819

Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention for caregivers of individuals with advanced PD
Number of subjects: 34
Study: 35482080

Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 17
Study: 35482127

Group type: EXPERIMENTAL
Intervention: Autologous GM-CSF-secreting breast cancer vaccine
Number of subjects: 22
Study: 35482392

Group type: EXPERIMENTAL
Intervention: Eir web-based communication tool for symptom registration at home
Number of subjects: 134
Study: 35482408

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy with highly neutralizing plasma
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy with high neutralizing antibodies
Number of subjects: 30
Study: 35482538

Group type: EXPERIMENTAL
Intervention: Blinatumomab (15 μg/m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0

Group type: COMPARATOR
Intervention: HC3
Number of subjects: 0
Study: 35482768

Group type: EXPERIMENTAL
Intervention: Meeting PA guidelines (MVPA ≥30 min·d -1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity PA (MVPA)
Number of subjects: 100
Study: 35482910

Group type: EXPERIMENTAL
Intervention: TETA-2HCl treatment
Number of subjects: 77
Study: 35483358

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR inhibitors
Number of subjects: 0
Study: 35483396

Group type: EXPERIMENTAL
Intervention: Venetoclax plus intensive chemotherapy
Number of subjects: 279

Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 279
Study: 35483431

Group type: EXPERIMENTAL
Intervention: Sayana® Press injected every 4 months
Number of subjects: 750
Study: 35483480

Group type: EXPERIMENTAL
Intervention: Balloon undilatable lesions
Number of subjects: 558
Study: 35483736

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 PCR-positive patients (n=28)
Number of subjects: 48

Group type: COMPARATOR
Intervention: SARS-CoV-2 PCR-negative exposed controls (n=20)
Number of subjects: 48
Study: 35483792

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4740

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4740
Study: 35483796

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4776
Study: 35483876

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35484319

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg intravenously every 2 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Recommended dose of 15 mg/kg every 2 weeks for patients aged < 12 years or weighing < 40 kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Recommended adult flat dose of 800 mg every 2 weeks for patients aged ≥ 12 years and weighing ≥ 40 kg
Number of subjects: 21
Study: 35484400

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: regorafenib
Number of subjects: 529
Study: 35484469

Group type: EXPERIMENTAL
Intervention: Meningococcal meningitis patients
Number of subjects: 111
Study: 35484592

Group type: EXPERIMENTAL
Intervention: High stress due to indistinct organization and conflicts
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: High stress due to individual demands and commitment
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Low influence at work
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: High interference between work and leisure time
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: High stress due to both indistinct organization and conflicts and individual demands and commitment
Number of subjects: 232
Study: 35484614

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS) or combined modality EBUS/endoscopic ultrasound (EUS-B) for staging
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endoscopic mediastinal staging
Number of subjects: 10
Study: 35484649

Group type: EXPERIMENTAL
Intervention: Itolizumab (anti-CD6 monoclonal antibody)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Itolizumab
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study: 35484817

Group type: EXPERIMENTAL
Intervention: Twice-daily enoxaparin (initial dose: 0.5mg/kg per dose; max: 60mg; target anti-Xa activity: 0.20-0.49IU/mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Twice-daily enoxaparin
Number of subjects: 40
Study: 35485211

Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel
Number of subjects: 0

Group type: COMPARATOR
Intervention: conventional care
Number of subjects: 0
Study: 35485232

Group type: EXPERIMENTAL
Intervention: LRP patients
Number of subjects: 390

Group type: COMPARATOR
Intervention: non-LRP patients
Number of subjects: 390
Study: 35485234

Group type: EXPERIMENTAL
Intervention: Person-centred and thriving-promoting intervention (staff educational programme)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 292
Study: 35485327

Group type: EXPERIMENTAL
Intervention: Lung ventilation and perfusion (LVP) by LVP scintigraphy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tc-99m-labeled albumin-gated blood-pool scintigraphy
Number of subjects: 20
Study: 35485802

Group type: EXPERIMENTAL
Intervention: Follow-up prevalence of any disorder
Number of subjects: 8996

Group type: EXPERIMENTAL
Intervention: Incidence of probable mental disorders
Number of subjects: 8996

Group type: EXPERIMENTAL
Intervention: Persistence of mental disorders
Number of subjects: 8996

Group type: EXPERIMENTAL
Intervention: Risk factor - Prioritising Covid-19 patients
Number of subjects: 8996

Group type: EXPERIMENTAL
Intervention: Risk factor - Personal health-related stress
Number of subjects: 8996

Group type: EXPERIMENTAL
Intervention: Risk factor - Interpersonal stress
Number of subjects: 8996

Group type: EXPERIMENTAL
Intervention: Risk factor - Significant income loss
Number of subjects: 8996
Study: 35485908

Group type: EXPERIMENTAL
Intervention: Factory-calibrated Continuous Glucose Monitor (CGM)
Number of subjects: 20
Study: 35485920

Group type: COMPARATOR
Intervention: Obsessive-compulsive disorder (OCD) group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Younger participants with OCD
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 200
Study: 35485937

Group type: EXPERIMENTAL
Intervention: Fluorine 18 fluoromisonidazole (18F-FMISO) imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35486436

Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical therapy (control)
Number of subjects: 20
Study: 35486437

Group type: EXPERIMENTAL
Intervention: mHealth intervention (standard clinical practice + mobile app)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical practice (control group)
Number of subjects: 0
Study: 35486475

Group type: EXPERIMENTAL
Intervention: Midostaurin plus intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and 1-year midostaurin maintenance therapy
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Midostaurin plus intensive chemotherapy
Number of subjects: 440
Study: 35486638

Group type: EXPERIMENTAL
Intervention: Lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks
Number of subjects: 28
Study: 35487034

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 22